Trevena Inc (TRVN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Trevena Inc (TRVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013219
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Trevena Inc (Trevena) is a biopharmaceutical company that discovers and develops G-protein coupled receptor targeted medicines. The company’s products include RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena’s TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. The company’s GPCR is associated with beneficial versus adverse biological effects. Its TRV250 is an oral delta opioid biased ligand for treatment of refactory migraine. Trevena is headquartered in King of Prussia, Pennsylvania, the US.

Trevena Inc (TRVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Trevena Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Trevena Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Trevena Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Trevena To Raise US$60 Million In Series C Financing 11
Partnerships 13
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 13
Equity Offering 14
Trevena Raises USD73 Million in Public Offering of Shares 14
Trevena Raises USD51.4 Million in Public Offering of Shares 16
Trevena Completes Underwriters Exercise Of Over-Allotment Of IPO For US$66.6 Million 18
Trevena Inc – Key Competitors 20
Trevena Inc – Key Employees 21
Trevena Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Nov 07, 2017: Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data 23
Aug 03, 2017: Trevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update 25
May 04, 2017: Trevena Reports First Quarter 2017 Financial Results and Provides Corporate Update 27
Mar 08, 2017: Trevena Reports Full Year 2016 Earnings 28
Nov 03, 2016: Trevena Reports Third Quarter 2016 Financial Results and Provides Corporate Update 30
Aug 04, 2016: Trevena Reports Second Quarter 2016 Financial Results and Provides Corporate Update 31
May 05, 2016: Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update 32
Mar 09, 2016: Trevena Reports Full Year 2015 Financial Results 33
Corporate Communications 35
Aug 14, 2017: Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 35
Product News 36
10/27/2016: Trevena Announces Highlights from Recent Presentations 36
Product Approvals 37
Feb 22, 2016: Trevena Receives FDA Breakthrough Therapy Designation for Oliceridine 37
Clinical Trials 38
Apr 06, 2017: Trevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting 38
Feb 21, 2017: Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain 40
Jan 04, 2017: Trevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute Pain 42
Jun 08, 2016: Trevena Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain 43
May 02, 2016: Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine 44
Jan 19, 2016: Trevena Announces Initiation of Oliceridine Phase 3 Clinical Program 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Trevena Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Trevena Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Trevena Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Trevena Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Trevena To Raise US$60 Million In Series C Financing 11
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 13
Trevena Raises USD73 Million in Public Offering of Shares 14
Trevena Raises USD51.4 Million in Public Offering of Shares 16
Trevena Completes Underwriters Exercise Of Over-Allotment Of IPO For US$66.6 Million 18
Trevena Inc, Key Competitors 20
Trevena Inc, Key Employees 21

★海外企業調査レポート[Trevena Inc (TRVN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fidia farmaceutici SpA-製薬・医療分野:企業M&A・提携分析
    Summary Fidia farmaceutici SpA (Fidia), a subsidiary of P&R S.p.A., is a healthcare products provider that specializes in research, development and manufacturing of hyaluronic acid-based products. The company develops and commercializes products for specific therapeutic areas which includes joint he …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Commonwealth Bank of Australia:戦略・SWOT・企業財務分析
    Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report Summary Commonwealth Bank of Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Amcor Limited:企業の戦略・SWOT・財務情報
    Amcor Limited - Strategy, SWOT and Corporate Finance Report Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Travis Perkins plc:企業の戦略・SWOT・財務分析
    Travis Perkins plc - Strategy, SWOT and Corporate Finance Report Summary Travis Perkins plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • HSH Nordbank Private Banking:企業の戦略・SWOT・財務情報
    HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSH Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • The Bank of Nagoya, Ltd.:企業の戦略・SWOT・財務情報
    The Bank of Nagoya, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Bank of Nagoya, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • KB Home:企業の戦略・SWOT・財務分析
    KB Home - Strategy, SWOT and Corporate Finance Report Summary KB Home - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Medistim ASA (MEDI):企業の財務・戦略的SWOT分析
    Summary MediStim ASA (MediStim) is a medical device company that manufactures and markets medical products for cardiac, vascular and transplant surgeries. The company’s products include MiraQ cardiac, MiraQ vascular, MiraQ ultimate system, imaging probes, flow probes, VeriQ C and VeriQ systems. Its …
  • Zhuhai Holdings Investment Group Co Ltd:企業の戦略・SWOT・財務分析
    Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • HemaCare Corp (HEMA):医療機器:M&Aディール及び事業提携情報
    Summary HemaCare Corp (HemaCare) is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, cord blood, and bone marrow. It spans its expertise in isolations, custom cell collections and testing of p …
  • Grindeks (GRD1R):製薬・医療:M&Aディール及び事業提携情報
    Summary Grindeks focuses on the research, development, manufacture and marketing of novel pharmaceuticals, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and cancer therapeutic categories …
  • AF-Consult Switzerland AG:企業の戦略的SWOT分析
    AF-Consult Switzerland AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Quaterra Resources Inc (QTA):企業の財務・戦略的SWOT分析
    Summary Quaterra Resources Inc (Quaterra Resources) is a copper exploration company that acquires and operates copper projects. The company's activities include acquisition, exploration and development of gold, silver, and copper deposits in Canada. Its projects comprise Quaterra’s Yerington Copper …
  • Juno Therapeutics Inc:企業の戦略的SWOT分析
    Juno Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • UPL Ltd (UPL):企業の財務・戦略的SWOT分析
    UPL Ltd (UPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Shri Lakshmi Cotsyn Ltd.:企業の戦略・SWOT・財務情報
    Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Talanx AG:企業の戦略・SWOT・財務情報
    Talanx AG - Strategy, SWOT and Corporate Finance Report Summary Talanx AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Cairn Energy Plc (CNE):企業の財務・戦略的SWOT分析
    Cairn Energy Plc (CNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆